
Insilico Medicine to Present AI-Designed Cancer Drug Data at ESMO 2026
A novel AI-generated inhibitor, ISM6331, is set to take center stage at the upcoming European Society for Medical Oncology Congress in Madrid. Insilico Medicine will present first-in-human data from a Phase 1 trial, marking a significant step in the company's efforts to treat mesothelioma and advanced solid tumors.



:max_bytes(150000):strip_icc():format(jpeg)/GettyImages-2212073679-35f87660f5a64ff5962b11364b4f5e09.jpg)


















